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Effectiveness of a triple-drug regimen for global elimination
of lymphatic filariasis: a modelling study
Michael A Irvine, Wilma A Stolk, Morgan E Smith, Swaminathan Subramanian, Brajendra K Singh, Gary J Weil, Edwin Michael,
T Deirdre Hollingsworth

Summary

Background Lymphatic filariasis is targeted for elimination as a public health problem by 2020. The principal approach
used by current programmes is annual mass drug administration with two pairs of drugs with a good safety profile.
However, one dose of a triple-drug regimen (ivermectin, diethylcarbamazine, and albendazole) has been shown to
clear the transmissible stage of the helminth completely in treated individuals. The aim of this study was to use
modelling to assess the potential value of mass drug administration with the triple-drug regimen for accelerating
elimination of lymphatic filariasis in different epidemiological settings.
Methods We used three different transmission models to compare the number of rounds of mass drug administration
needed to achieve a prevalence of microfilaraemia less than 1% with the triple-drug regimen and with current
two-drug regimens.
Findings In settings with a low baseline prevalence of lymphatic filariasis (5%), the triple-drug regimen reduced the
number of rounds of mass drug administration needed to reach the target prevalence by one or two rounds, compared
with the two-drug regimen. For areas with higher baseline prevalence (10–40%), the triple-drug regimen strikingly
reduced the number of rounds of mass drug administration needed, by about four or five, but only at moderate-to-high
levels of population coverage (>65%) and if systematic non-adherence to mass drug administration was low.
Interpretation Simulation modelling suggests that the triple-drug regimen has potential to accelerate the elimination
of lymphatic filariasis if high population coverage of mass drug administration can be achieved and if systematic
non-adherence with mass drug administration is low. Future work will reassess these estimates in light of more
clinical trial data and to understand the effect on an individual country’s programme.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.

Introduction
Lymphatic filariasis is a neglected tropical disease caused
by filarial nematodes that is prevalent in large parts of the
tropics and subtropics.1 Currently, 790 million people are at
risk of the disease and 68 million are infected, with a
further 20 million suffering from chronic morbidity.2–4
In 2000, the Global Programme to Eliminate Lymphatic
Filariasis (GPELF) was launched by WHO with the primary
goal of global elimination of filariasis through mass drug
administration of pairs of anthelmintic drugs (albendazole
in combination with either ivermectin or diethyl
carbamazine).5 The campaign has seen unprece
dented
scale-up, with 22 countries currently undergoing mass
drug administration at full geographic coverage and a
further 18 countries in surveillance after mass drug
administration. This programme was made possible by
donation of diethylcarbamazine citrate by Eisai, albendazole
by GlaxoSmithKline, and ivermectin by Merck.
Current guidelines require at least five rounds of
mass drug administration, resulting in a microfilaraemia
prevalence of less than 1%, as measured using a trans
mission assessment survey across an implementation
unit, preceded by an initial pre-transmission assessment
www.thelancet.com/infection Vol 17 April 2017

survey at particular sites.6,7 These programmes have
resulted in huge health gains internationally among lowincome populations.6 However, in 2014, 11 countries had
yet to begin their mass drug administration programmes;
moreover, some districts or other focused areas in several
countries have not yet reached elimination targets despite
10 years or more of mass drug administration.8 Several
factors can lead to a programme failing to reach its
targets—eg, high prevalence of filariasis, poor population
coverage, partial effectiveness of drug regimens,
inadequate dose received, non-adherence because of fear
of side-effects, and failure for medicine to be delivered.9–12
For these scenarios, new strategies are needed to achieve
the elimination goals by 2020.
Findings of a clinical trial suggested that, by
combining the three drugs used to treat lymphatic
filariasis
(ivermectin,
diethylcarbamazine,
and
albendazole), improved efficacy for clearing the
transmissible stage of the filarial parasite Wuchereria
bancrofti (microfilariae) and sterilising adult filarial
worms could be achieved.13 The safety and efficacy of
this promising regimen for widespread use is the
subject of ongoing study. However, the triple-drug
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Research in context
Evidence before this study
We searched PubMed on Sept 20, 2016, with the terms
“ivermectin”, “DEC”, “albendazole”, and “lymphatic filariasis”.
All studies that included ivermectin, diethylcarbamazine, and
albendazole in a trial of individual clinical effectiveness for
lymphatic filariasis infection were included. Findings showed
that the triple-drug regimen resulted in a much stronger and
more prolonged clearance of microfilaraemia. The aim of this
study was to use simulation modelling to assess the potential
effect of a three-drug regimen of ivermectin,
diethylcarbamazine, and albendazole for accelerating
elimination of lymphatic filariasis in different epidemiological
settings.
Added value of this study
We used three transmission models to simulate the effect of
triple-drug mass drug administration in different scenarios and
with different levels of coverage to estimate the added benefit of

See Online for appendix
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regimen would not be suitable for all areas where
lymphatic filariasis is endemic because of contra
indications for diethylcarbamazine in regions where
onchocerciasis is endemic and for ivermectin in areas
where loiasis is endemic. Nevertheless, a triple-drug
regimen of ivermectin, diethylcarbamazine, and
albendazole holds great promise.
The additional value of the triple-drug regimen at the
population level—for reaching elimination targets more
quickly and with fewer rounds of mass treatment
compared with standard two-drug regimens—is a crucial
factor in the consideration of any change in use and must
be investigated for expected-use cases and scenarios.
Mathematical modelling can play a part by simulating
different scenarios and assessing the likely effect of a
triple-drug regimen under different assumptions.
We used three state-of-the-art lymphatic filariasis trans
mission models to assess the likely effect of the tripledrug regimen of ivermectin, diethylcarbamazine, and
albendazole in several scenarios, to understand the
extent of any potential benefit of the triple-drug regimen
over the standard two-drug strategy, and to investigate
the conditions under which this benefit is most
pronounced. Three models provide far greater robustness
and quantification of uncertainty in prediction versus
use of one model. Five broad scenarios are considered
from various plausible settings in which both the
dominant vector species and the baseline prevalence of
microfilariae are varied to reflect the current global
situation of lymphatic filariasis endemicity. These
scenarios include areas where no previous mass drug
administration campaign has been undertaken and those
where five rounds of mass drug administration were
insufficient to reduce the prevalence of infection to the
target of less than 1% needed for stopping mass drug
administration.

using ivermectin, diethylcarbamazine, and albendazole over
standard two-drug regimens. Our analysis allowed us to
extrapolate results from early clinical trial data to predict the likely
outcome of subnational triple-drug mass drug administration
programmes in different epidemiological settings.
Implications of all the available evidence
The triple-drug regimen has the potential to accelerate
achievement of elimination goals for lymphatic filariasis,
particularly in areas with high baseline prevalence. However,
a more effective treatment will not overcome issues of poor
population coverage or high systematic non-adherence in
subsets of the population, because of the long lifespan of adult
filarial worms. Therefore, a paradigm shift might be needed in
how these programmes are rolled out to realise the potential of
the triple-drug regimen and to relieve the burden of this
debilitating disease.

Methods

Study design
Clinical trial findings suggest that microfilariae clearance
by ivermectin, diethylcarbamazine, and albendazole is
likely to be 100%.13 Ongoing studies will refine this
estimate; therefore, our analysis is for the most optimistic
effect. In view of the evidence from the clinical trial,
we made two plausible efficacy assumptions for the new
triple-drug regimen on adult worms (appendix p 2). First,
we assumed that the combination of ivermectin,
diethylcarbamazine, and albendazole has the same
macrofilaricidal properties as albendazole and diethyl
carba
mazine (55%) and the remaining worms are
sterilised permanently; this assumption was denoted
IDA1. Second, we assumed that ivermectin, diethylcarba
mazine, and albendazole has the same macrofilaricidal
properties as albendazole and diethylcarbamazine (55%);
this assumption was referred to as IDA2. These
assumptions are compared with a counterfactual
regimen of albendazole and diethylcarbamazine because
we are only considering areas that are not co-endemic
with onchocerciasis, which would prohibit use of
diethylcarbamazine.
A pertinent question is, with a 100% effective regimen,
whether one round of treatment would be sufficient in
driving the prevalence of microfilariae below 1%
(appendix p 1). To assess the effect of one round of
treatment, we used a simple model of infection in which
every individual has either microfilaraemia or no
infection (amicrofilaraemia), and the combined regimen
of ivermectin, diethylcarbamazine, and albendazole is
assumed to permanently clear microfilaraemia with
100% efficacy (IDA1). This estimate was compared
with the counterfactual regimen (albendazole and
diethylcarbamazine), assuming no transmission and
23·1% clearance of microfilariae.14
www.thelancet.com/infection Vol 17 April 2017
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We compared three models of lymphatic filariasis
transmission to analyse the projected efficacy of the
triple-drug regimen of ivermectin, diethylcarbamazine,
and albendazole: LYMFASIM, EPIFIL, and TRANSFIL
(appendix pp 4–11).15–18 LYMFASIM and TRANSFIL
are stochastic microsimulations including detailed
descriptions of individuals’ burden as well as systematic
non-adherence. EPIFIL is a deterministic, age-structured,
population-based model of lymphatic filariasis infection
including a juvenile, adult worm, and microfilariae stage
as well as a larval stage in the mosquito population.
All models have been fitted previously to various agestructured microfilaraemia data (age-structured crosssectional data, trends in prevalence of microfilariae
during interventions, association between prevalence of
microfilariae and biting rate) and have been compared
robustly with other data—eg, circulating filarial antigen
prevalence.15,16,19–21 We assessed the models at their standard
parameter settings so that every model’s most confident
predictions could be used, as they would have been if no
direct comparison with other models were available.
We then compared predictions for several standardised
scenarios and elucidated the causes of differences.
We presented the effect of ivermectin, diethyl
carbamazine, and albendazole in three typical scenarios,
capturing a range of transmission settings (appendix p 3).
First, we used an Asian setting with a 5% baseline
prevalence of microfilariae, where Culex species are
dominant (eg, India, Sri Lanka, and Indonesia). Second,
we used an African setting that is not co-endemic with
onchocerciasis or loiasis, with 10% baseline prevalence of
microfilariae, where Anopheles species are dominant and
bednet use is 0% or 50% (eg, Madagascar, Zambia, and
Zimbabwe). Third, we used a setting of Papua New Guinea,
with 40% prevalence of microfilariae, where Anopheles
species are dominant and bednet use is 0% or 50%.
To ascertain the effect of population coverage
and systematic non-adherence on the increased
effectiveness of ivermectin, diethylcarbamazine, and
albendazole, we did a sensitivity analysis of these
two factors in the TRANSFIL model. We chose
population coverage levels of 55%, 65%, and 75%.
We also considered high and low systematic nonadherence, in which a randomly chosen individual’s
decision on adhering to mass drug administration was
the same as their decision in the previous round 25% of
the time (low systematic non-adherence) or 75% of the
time (high systematic non-adherence).
In areas where elimination campaigns are currently
failing, several reasons could account for this occurrence,
but it is difficult to measure the main drivers of this
behaviour. We used TRANSFIL to investigate the
additional effect of ivermectin, diethylcarbamazine, and
albendazole under the three main hypotheses for why
a campaign might be failing to achieve its goals
after several rounds of mass drug administration
www.thelancet.com/infection Vol 17 April 2017

(appendix p 3). The first hypothesis is that the burden of
disease in the population is highly aggregated, meaning
that some individuals are disproportionately more
exposed than others. The second hypothesis is that
strong systematic non-adherence occurs when a group
of individuals consistently do not receive treatment. The
third hypothesis is that poor population coverage might
be present for individuals who are more highly exposed.
For each possible hypothesis, we undertook five rounds
of mass drug administration with the standard regimen,
after which either the standard regimen was continued
or the elimination campaign switched to the triple-drug
regimen of ivermectin, diethyl
carbamazine, and
albendazole.

Statistical analysis
The primary outcome measure was the number of
rounds of mass drug administration needed to reduce
the prevalence of microfilariae to below 1%, as recorded
1 year after implementation (transmission assessment
survey). Because two models assessed in the analysis of
scenarios are stochastic in nature (LYMFASIM and
TRANSFIL), and two models account for parameter
uncertainty (EPIFIL and TRANSFIL), there will be
uncertainty between runs. Therefore, we ran every
scenario and efficacy assumption for ivermectin,
diethylcarbamazine, and albendazole 200 times.
We aggregated the probability of reducing the
prevalence of microfilariae to below 1% over all
three models, using an equal weighting for all models.
We also recorded the probabilities for the individual
models.

Role of the funding source
The funder had no role in study design, data collection,
data analysis, data interpretation, or writing of the report.
100
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Procedures
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Figure 1: Effect of one round of triple-drug mass drug administration
Plot shows the probability of achieving target prevalence (<1%) when baseline microfilariae prevalence is 5% (blue
line), 10% (green line), and 15% (red line). (Inset) Illustration of setting with 5% prevalence (red spots), 95% not
infected (amicrofilaraemia; blue spots), and 65% population coverage (black circles).
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The corresponding author had full access to all the data
in the study and had final responsibility for the decision
to submit for publication.

A
100

Results

Probability of achieving <1% target (%)

80

60

40
Albendazole + diethylcarbamazine
IDA1
IDA2
TRANSFIL model
LYMFASIM model
EPIFIL model

20

0

B
100

Probability of achieving <1% target (%)

80

60

40

20

0

C

100

Probability of achieving <1% target (%)

80

60

40

20

0

454

Figure 1 shows the effect of one round of ivermectin,
diethylcarbamazine, and albendazole. Even in settings
with a low baseline prevalence of microfilariae, the
existing target of 65% population coverage is unlikely to
reduce the prevalence to below 1% with one round of
ivermectin, diethylcarbamazine, and albendazole. At a
microfilariae prevalence of 5%, a slight overlap can be
seen between individuals who are infected and those who
are treated at a coverage of 65% (figure 1, inset), resulting
in too small a reduction in prevalence. As population
coverage increases, the probability of reducing micro
filariae to less than 1% rises markedly; however, the
probability is only more than 80% when population
coverage exceeds 80%. By comparison, the counterfactual
regimen of albendazole and diethylcarbamazine had
negligible probability (<0·1%) of reducing prevalence of
microfilariae to target levels for any level of population
coverage (data not shown).
In the Asian scenario, with a low (5%) baseline
prevalence of microfilariae, the probability of achieving
the target of less than 1% prevalence of microfilariae was
moderately high with both the triple-drug and two-drug
regimens (figure 2A). After three rounds of mass drug
administration, averaged across models, the probability
of achieving the target prevalence with the existing twodrug regimen was 48%, compared with a 95% probability
with the triple-drug regimen. However, after five rounds
(the current standard protocol), the difference between
the regimens was smaller (95% with the two-drug
regimen vs 100% with the triple-drug regimen). Larger
gains were observed for the African scenario, with a
moderate (10%) baseline prevalence of microfilariae
(figure 2B). Here, the probability of achieving the less
than 1% target prevalence after five rounds of mass drug
administration was 55% for the two-drug regimen
compared with 98% for the most optimistic, three-drug,
100% worm sterilisation assumption (IDA1). In the Papua
New Guinea scenario, with the highest (40%) baseline
prevalence of microfilariae, the probability of achieving

1

2

3

4
5
6
7
Rounds of mass drug administration (n)

8

9

10

Figure 2: Effect of triple-drug regimen in areas with no previous mass drug
administration
Plots show the probability of achieving target prevalence (<1%) with two-drug
(blue line) and triple-drug (green and red lines) regimens. Solid lines indicate a
model-averaged estimate and dashed lines are estimates from the individual
models. (A) Low prevalence setting (Asia, Culex spp, 5% baseline prevalence of
microfilariae, no long-lasting insecticide-treated nets). (B) Moderate prevalence
setting (Africa, not co-endemic with onchocerciasis, Anopheles spp, 10% baseline
prevalence of microfilariae, no long-lasting insecticide-treated nets). (C) High
prevalence setting (Papua New Guinea, Anopheles spp, 40% baseline prevalence
of microfilariae, no long-lasting insecticide-treated nets). IDA1=ivermectin,
diethylcarbamazine, and albendazole as efficacious as two-drug regimen and
100% worm sterilisation. IDA2=ivermectin, diethylcarbamazine, and
albendazole as efficacious as two-drug regimen.
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Figure 3: Relative effects of population coverage and systematic non-adherence
Plots show the probability of achieving target prevalence (<1%) with two-drug
(blue line) and triple-drug (green line) regimens with high and low systematic
non-adherence (dashed lines) when population coverage is (A) poor (55%),
(B) standard (65%), and (C) high (75%). IDA1=ivermectin, diethylcarbamazine,
and albendazole as efficacious as two-drug regimen and 100% worm
sterilisation.

www.thelancet.com/infection Vol 17 April 2017
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the target prevalence of less than 1% was greater with
five rounds of the triple-drug regimen than with the
standard two-drug regimen (6% with the two-drug
regimen vs 50% with the triple-drug regimen; figure 2C).
When the number of rounds of mass drug administration
rose to six, the triple-drug regimen increased the
chances of reaching the target prevalence by a factor of
five (16% vs 80%). Varying the proportion of worm
sterilisation (90–100%) did not greatly affect the
probability of reaching the threshold target (appendix p 15).
Compared with the standard two-drug regimen, the
number of rounds of mass drug administration needed
to achieve the less than 1% target prevalence, and the
probability of a large number of rounds being needed by
chance for a particular parameter set (fewer outliers in
the box plots; appendix pp 12, 13), was much lower with
the triple-drug regimen. The amount of variation is
different for every model, but the results are qualitatively
consistent. The reduction in the range of rounds between
the standard two-drug regimen and the triple-drug
regimen was between four and five rounds for low,
moderate, and high prevalence settings. This finding can
also be seen as reducing the likelihood of needing more
than five rounds of mass drug administration.
Changing population coverage has a strong effect on
reducing the number of rounds needed to achieve less
than 1% prevalence of microfilariae, for both the triple-drug
regimen of ivermectin, diethylcarbamazine, and alben
dazole and the two-drug regimen of albendazole and
diethylcarbamazine (figure 3). Increasing coverage from
65% to 75% reduces the number of rounds needed to have
a 95% probability of reaching the target prevalence, from
seven to three rounds for the two-drug regimen and from
three to two rounds for the triple-drug regimen. High
systematic non-adherence has a striking effect on the
outcome of mass drug administration with poor levels of
coverage (55%) increasing the number of rounds needed
to achieve 95% probability from seven to ten rounds for
the two-drug regimen and four to eight rounds for the
triple-drug regimen (appendix p 14). However, at higher
levels of coverage (75%), the effect is less severe, with the
number of rounds needed for 95% probability increasing
by one for both the two-drug and three-drug regimens.
The additive effect of using long-lasting insecticidetreated nets with mass drug administration was
investigated for the scenarios from Africa and Papua
New Guinea, where Anopheles spp is the dominant vector
(figure 4). Use of bednets had only a marginal effect on
the number of rounds of mass drug administration
needed to reach the 1% microfilariae prevalence
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threshold in both the moderate and high prevalence
settings.
The table shows the number of rounds of mass drug
administration needed to achieve a prevalence of

Rounds of mass drug administration needed to
achieve <1% target (%)

A
12
10
8

Discussion

6
4
2
0

Rounds of mass drug administration needed to
achieve <1% target (%)

B

12
10
8
6
4
2
0

EPIFIL model

TRANSFIL model

LYMFASIM model

Figure 4: Effect of bednets on efficacy of triple-drug regimen
Boxplots show data for settings where Anopheles spp are the dominant vector.
Red boxes denote scenarios without bednets and blue boxes denote scenarios
with bednets. Solid black line represents the median round; coloured box
represents the IQR; whiskers represent the 5th and 95th percentiles.
(A) Moderate prevalence setting (Africa, Anopheles spp, 10% prevalence of
microfilariae, no previous mass drug administration). (B) High prevalence
setting (Papua New Guinea, Anopheles spp, 40% prevalence of microfilariae,
no previous mass drug administration).
High heterogeneity
in exposure

Systematic
non-adherence

Poor population
coverage of highly
exposed individuals

Low prevalence setting
Albendazole and diethylcarbamazine

1 (1–2)

2 (1–3)

4 (1–13)

Ivermectin, diethylcarbamazine,
and albendazole

1 (1–2)

1 (1–3)

4 (1–8)

Moderate prevalence setting
Albendazole and diethylcarbamazine

2 (1–8)

3 (1–9)

10 (1–14)

Ivermectin, diethylcarbamazine,
and albendazole

1 (1–3)

2 (1–6)

6 (1–14)

Data are median number of rounds (95% CI). Based on simulations with TRANSFIL in a low prevalence setting
(Asia, Culex spp, 5% prevalence of microfilariae, no previous mass drug administration, no long-lasting insecticide-treated
nets) and a setting with moderate prevalence (Africa, not co-endemic with onchocerciasis, Anopheles spp, 10% prevalence
of microfilariae, no previous mass drug administration, no long-lasting insecticide-treated nets).

Table: Analysis of hypotheses for failing elimination campaigns
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microfilariae less than 1% after the initial five rounds of
mass drug administration, for every scenario related to
stagnation of the elimination campaign. The triple-drug
regimen was predicted to save one round of mass drug
administration versus the two-drug regimen of albendazole
and diethylcarbamazine, with a greater effect when
campaign stagnation was attributable to poor population
coverage of heavily infected individuals in a setting of
moderate prevalence, reducing the medium number of
rounds from ten to six.
The triple-drug regimen of ivermectin, diethyl
carbamazine, and albendazole represents an exciting
new development for GPELF and could potentially
reduce significantly the number of doses of anthelmintic
drugs needed by this WHO campaign. Several questions
remain open surrounding the efficacy of this triple-drug
regimen at the population level and with respect to its
ability to reinvigorate campaigns that have stagnated,
as well as overcome issues such as poor population
coverage or adherence. Here, we have shown a first step
towards understanding these issues by comparing
several different generic scenarios between the current
regimen of albendazole and diethylcarbamazine and the
new regimen of ivermectin, diethyl
carbamazine, and
albendazole, using three current models of lymphatic
filariasis infection.
Existing mass drug administration programmes are
designed around what was perceived to be achievable
effective population coverage (65%) and duration to match
the life expectancy of the adult worm (5 years). However, the
level of coverage might not be enough to achieve elimination
targets in all settings.15,22,23 Because ivermectin, diethyl
carbamazine, and albendazole could lead to permanent
sterilisation or killing of adult worms, shorter timeframes
for campaigns can be considered, particularly if population
coverage is higher. A shorter timeframe has the potential to
reduce issues such as programme fatigue and poor coverage
by allowing a more focused intervention and extra effort to
optimise coverage.
Although at least 65% population coverage is recom
mended, many intervention units report higher levels.23
Notwithstanding issues related to true coverage, both
systematic non-adherence and the drug regimen have less
of an effect with high levels of coverage with respect to the
probability of success for a campaign given a specified
number of rounds (figure 3). This finding highlights that,
with good population coverage, a campaign is able to
overcome some of the possible stagnation issues.
In addressing the 2020 goals for elimination of
lymphatic filariasis, our results indicate that a campaign
will have a greater probability of success if switching
to ivermectin, diethylcarbamazine, and albendazole
provides the same level of coverage as would be expected
under the existing two-drug regimen. In a setting with
moderate baseline prevalence of microfilariae, the
www.thelancet.com/infection Vol 17 April 2017
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probability of a campaign’s success increases by 70%;
however, in a low prevalence setting, the gains are
modest, only increasing the chances of success by
about 20%. In high prevalence settings, the chances of
success in achieving 2020 targets are only 35%.
At all levels of population coverage, systematic nonadherence restricts the potential effect of ivermectin,
diethylcarbamazine, and albendazole. This finding
suggests that although more effective, the triple-drug
regimen is still susceptible to issues that limit the
effectiveness of current mass drug administration
regimens.24 However, ivermectin, diethylcarbamazine,
and albendazole consistently outperformed the current
two-drug regimen in all simulation studies, including
scenarios with high systematic non-adherence. This
finding shows that ivermectin, diethylcarbamazine,
and albendazole can accelerate lymphatic filariasis
elimination programmes across various situations.
For the three models, there was variation in the
number of rounds needed to push prevalence below 1%
for each of the model runs. Stochastic variation and
fluctuation in population parameters can lead to
situations in which reduction in prevalence is more
difficult to achieve even when other variables—eg, the
average infection rate—are constant. The extent of these
more extreme cases was reduced when ivermectin,
diethylcarbamazine, and albendazole was implemented,
versus the current two-drug regimen of albendazole and
diethylcarbamazine, particularly with high transmission.
This finding is especially encouraging for areas with
high baseline prevalence of microfilariae or for settings
in which implementation of mass drug administration
has so far been unable to reduce prevalence of lymphatic
filariasis to threshold targets.24
Our study has several limitations. First, because only
a small study sample has been published up to now
with respect to individual efficacy of ivermectin,
diethylcarbamazine, and albendazole, the efficacy of
the triple-drug regimen is still uncertain. Second, we
did not aim to capture any specific country scenario
with our modelling analysis; rather, we used selected
scenarios that were representative of conditions in
endemic regions. Therefore, we aimed to investigate
overall patterns. Finally, the outcome measure chosen
in our study was the number of rounds of mass drug
administration to achieve WHO pre-transmission
assessment survey guidelines of less than 1%
microfilaraemia to directly address policy-relevant
questions about when specific settings are able to move
into the post-mass drug administration phase. However,
a further question asks what the probability of
elimination is once a region has entered the
transmission assessment survey phase, which is not
addressed here.
In conclusion, our modelling results suggest that the
triple-drug regimen of ivermectin, diethylcarbamazine,
and albendazole has great potential for accelerating
www.thelancet.com/infection Vol 17 April 2017

elimination of lymphatic filariasis in many settings,
which is important in view of WHO’s ambitious target
for global elimination by 2020. This study shows that
although greater gains can be made with ivermectin,
diethylcarbamazine, and albendazole, the regimen
cannot fully overcome some challenges that mass drug
administration campaigns face, such as systematic
non-adherence and poor population coverage. However,
if effective coverage can be achieved, ivermectin,
diethylcarbamazine, and albendazole should help
countries achieve elimination of lymphatic filariasis
more quickly across a diverse number of settings.
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